PIK3CA GENE EDITING IN BREAST CANCER CELL LINES
Links to Files
Permanent Link
Author/Creator
Author/Creator ORCID
Date
Type of Work
Department
Hood College Biology
Program
Biomedical and Environmental Science
Citation of Original Publication
Rights
Subjects
Abstract
This project is designed to show that mutations in PIK3CA gene cause some HER2+ breast cancer
patients to not respond to Trastuzumab and Lapatinib therapy. Experimental design is to correct PIK3CA
mutations in a collection of breast cancer cell lines by editing using CRISPR. The conformation of the
hypothesis is based on regaining cell lines with edited PIK3CA sensitive to treatment.